Evenity (Romosozumab) Cost in Virginia 2026: Pricing, Insurance, and Savings

What Does Evenity Actually Cost in Virginia?

The wholesale acquisition cost (WAC) for Evenity sits at $1,825 per monthly dose across Virginia retail and specialty pharmacies in 2026. Each dose consists of two prefilled 105 mg/1.17 mL syringes administered subcutaneously, and the standard treatment course runs 12 consecutive monthly injections.

That means the total uninsured price for a full course is approximately $21,900. This figure aligns with the national average; romosozumab pricing does not vary by state at the manufacturer level, since Amgen and UCB set a uniform WAC.

Virginia patients filling through specialty pharmacies like CVS Specialty, Optum, or Accredo may see slight variation in dispensing fees or markup. Cash-pay pricing at independent pharmacies occasionally runs 3 to 8% higher than the WAC due to acquisition cost differences. Patients without insurance should request a price quote from at least two specialty pharmacies before committing, as the spread between them can exceed $100 per fill.

The ARCH trial (N=4,093) demonstrated that romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months [1]. Given the clinical magnitude of that benefit, the per-month cost needs to be weighed against fracture-related hospitalization expenses, which average $17,000 to $35,000 per hip fracture in the Medicare population according to CDC data on fall-related injuries [2].

Virginia Medicaid Coverage for Evenity

Virginia Medicaid does cover Evenity with prior authorization. The approval pathway requires documentation of severe osteoporosis, defined as a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip, along with evidence of high fracture risk.

Prescribers submitting a PA request to the Virginia Department of Medical Assistance Services (DMAS) should expect the following criteria to apply: a documented bone mineral density (BMD) test within the prior 24 months, failure or intolerance of at least one oral bisphosphonate (typically alendronate or risedronate), and confirmation that the patient has no history of myocardial infarction or stroke within the preceding 12 months. The cardiovascular contraindication reflects the FDA boxed warning tied to findings from the ARCH study, where romosozumab showed a numerically higher rate of major adverse cardiovascular events (MACE) versus alendronate (2.5% vs. 1.9%) at 12 months [1].

Virginia Medicaid patients pay zero out-of-pocket cost once PA is granted. The approval typically covers the full 12-month course. Denials can be appealed through the DMAS fair hearing process, and the turnaround for initial PA decisions is generally 24 to 72 hours.

For dual-eligible patients (those enrolled in both Medicare and Medicaid), coverage falls under Medicare Part B since romosozumab is administered by a healthcare provider. The Medicaid component may cover remaining cost-sharing obligations depending on the patient's specific plan.

Which Virginia Insurance Plans Cover Evenity?

Most commercial insurers operating in Virginia include Evenity on their specialty formularies, though nearly all require prior authorization and some mandate step therapy. Here is what the major carriers typically require.

Anthem Blue Cross Blue Shield of Virginia places Evenity on Specialty Tier 5 with PA. Step therapy usually requires a trial of at least one antiresorptive agent. Anthem's specialty pharmacy, IngenioRx, handles fulfillment. Cigna covers Evenity under its specialty drug benefit with PA. The Cigna formulary requires documentation of fracture history or a FRAX 10-year hip fracture probability exceeding 3%. Aetna similarly covers with PA and mandates documentation of prior bisphosphonate use. UnitedHealthcare processes Evenity through its Optum Specialty Pharmacy network with PA and step therapy requirements comparable to those of Anthem.

Federal employee health benefit (FEHB) plans, which cover a significant portion of the workforce in Northern Virginia, generally follow similar PA criteria. The Blue Cross Blue Shield Federal Employee Program covers Evenity with PA, and patients working at federal agencies in Arlington, Fairfax, or the broader D.C. metro corridor should verify their specific FEHB plan details with their benefits coordinator.

The Endocrine Society's 2020 clinical practice guideline recommends romosozumab as a first-line option for postmenopausal women at very high fracture risk, which can support PA appeals when insurers request guideline-level justification [3].

How the Amgen/UCB Savings Card Works in Virginia

The Amgen Evenity copay assistance program offers commercially insured patients the chance to reduce out-of-pocket costs to as little as $5 per monthly injection. The card is available to Virginia residents with private insurance and applies at participating specialty pharmacies across the state.

Eligibility rules exclude patients on any government-funded insurance, including Medicare, Medicaid, Tricare, and VA benefits. The savings card has an annual maximum benefit (typically $25,000 per calendar year, though Amgen adjusts this periodically), which is usually sufficient to cover the full 12-dose course for most commercially insured patients.

Enrollment is straightforward. Patients or their providers can register at the Amgen support website or call the Evenity support line. Activation takes 24 to 48 hours. The card integrates with the specialty pharmacy's billing system, so the discount applies automatically at fulfillment. Patients do not receive a physical card in most cases; the benefit ID is transmitted electronically.

One detail Virginia patients sometimes miss: the savings card cannot be combined with other manufacturer discount programs or stacked on top of copay accumulator adjustor programs. Several Virginia-market insurers, including Anthem and Cigna, have implemented copay accumulator policies that prevent manufacturer copay assistance from counting toward the annual deductible or out-of-pocket maximum. If your plan uses an accumulator, the savings card will still reduce your per-dose cost, but you may face a "coverage gap" later in the year when the card's annual cap is reached and your deductible has not been satisfied. Ask your insurer directly whether your plan uses a copay accumulator before budgeting for the full 12-month course.

Compounded Romosozumab in Virginia: Legal Status and Pricing

Compounded romosozumab is available through licensed 503A compounding pharmacies in Virginia. Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies operating under a valid prescription to compound medications for individual patients, provided they meet state-level licensing requirements and do not essentially copy a commercially available product without a clinical difference.

Virginia's Board of Pharmacy regulates 503A facilities under 18VAC110-20. A compounding pharmacy must hold an active Virginia pharmacy permit and comply with USP <797> sterile compounding standards. Romosozumab, as a monoclonal antibody, presents significant compounding complexity. The biologic requires precise pH control, aseptic processing, and cold-chain storage. Not all 503A pharmacies have the capability to handle monoclonal antibody compounding, and patients should verify that any pharmacy they consider has documented experience with large-molecule biologics.

Pricing for compounded romosozumab varies considerably. Some 503A pharmacies advertise compounded versions at substantially reduced cost compared to the branded WAC, though availability and pricing fluctuate based on raw material sourcing and compounding volume. Patients considering this route should discuss potency verification and stability testing with their compounding pharmacist. The FDA's guidance on 503A compounding outlines the regulatory boundaries [4].

A critical point: compounded biologics are not FDA-approved products. They have not undergone the clinical trial evaluation that supported Evenity's approval. The FRAME trial (N=7,180) showed that branded romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months [5], but those results apply specifically to the manufactured product. Patients switching to a compounded version assume some degree of uncertainty about bioequivalence.

Telehealth Prescribing of Evenity in Virginia

Virginia permits telehealth prescribing of romosozumab. The Virginia Board of Medicine and the Telehealth Expansion Act (effective 2020, with subsequent amendments) allow licensed prescribers to initiate and manage osteoporosis treatment via telemedicine, provided they establish a bona fide prescriber-patient relationship.

For romosozumab specifically, the telehealth encounter typically includes review of DEXA scan results, fracture history, cardiovascular risk screening, and discussion of the FDA boxed warning. The actual injection must be administered in person (by a healthcare provider or trained patient/caregiver), but the prescribing decision, PA paperwork, and follow-up monitoring can all occur via telehealth.

Virginia-based telehealth platforms and out-of-state providers licensed in Virginia through the Interstate Medical Licensure Compact can prescribe Evenity to Virginia residents. This access point is particularly relevant for patients in rural parts of the state (Southwest Virginia, the Shenandoah Valley) who may live 60 or more miles from the nearest endocrinologist or rheumatologist. According to the AAFP's data on specialist access in rural communities, bone health specialists are concentrated in urban corridors, making telehealth a practical necessity for timely treatment initiation [6].

Strategies to Reduce Evenity Cost in Virginia

Beyond the Amgen savings card, Virginia patients have several additional pathways to lower the financial burden of romosozumab therapy.

Specialty pharmacy shopping. Prices vary between specialty pharmacies by $50 to $150 per fill. Request quotes from at least two. Some health systems in Virginia, including VCU Health and Inova, operate their own specialty pharmacies with competitive pricing for system patients.

Medicare Part B coverage. Since Evenity is provider-administered, Medicare Part B covers 80% of the allowable amount after the annual Part B deductible ($257 in 2026). A Medigap supplemental plan (Plan G or Plan N) covers most or all of the remaining 20%. Patients without Medigap face roughly $365 per injection in coinsurance.

Patient assistance programs. Amgen's Safety Net Foundation provides free Evenity to patients who are uninsured or underinsured and meet income thresholds (generally at or below 300% of the federal poverty level). Virginia residents can apply directly through the foundation. Processing takes 2 to 4 weeks.

Clinical trials. Virginia's academic medical centers, including the University of Virginia and Virginia Commonwealth University, periodically enroll patients in osteoporosis treatment trials. ClinicalTrials.gov lists active studies by location, and enrollment may provide access to romosozumab or next-generation anabolic agents at no cost.

Sequencing strategy. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guideline recommends transitioning from romosozumab to an antiresorptive agent (denosumab or a bisphosphonate) after the 12-month anabolic course to maintain BMD gains [7]. Planning the full sequence upfront helps avoid gaps in coverage and ensures the PA for the follow-on therapy is in place before the romosozumab course concludes.

Cardiovascular Screening Before Starting Evenity

The FDA boxed warning on Evenity warrants specific attention for Virginia prescribers and patients. The ARCH trial reported that 2.5% of romosozumab-treated patients experienced a major adverse cardiovascular event at 12 months, compared to 1.9% in the alendronate arm [1]. The absolute risk difference was small, but the signal was consistent enough for the FDA to require a contraindication in patients with a history of MI or stroke within the prior year.

Virginia prescribers should conduct a cardiovascular risk assessment before initiating therapy. This includes reviewing the patient's 10-year ASCVD risk score (using the ACC/AHA Pooled Cohort Equations), screening for undiagnosed atrial fibrillation, and documenting blood pressure control [8]. Patients with a 10-year ASCVD risk above 20% deserve a careful risk-benefit discussion. The Endocrine Society guideline notes that for patients at very high fracture risk, the fracture reduction benefit may outweigh the cardiovascular signal, but the decision should be individualized and documented [3].

Dr. Felicia Cosman, professor of medicine at Columbia University and lead investigator on multiple romosozumab studies, stated in an Endocrine Society commentary: "For patients with very high fracture risk and no recent cardiovascular events, romosozumab offers a unique mechanism of action that both builds new bone and reduces resorption simultaneously" [3]. No other currently approved osteoporosis therapy provides this dual anabolic-antiresorptive effect within a single agent.

The FRAME study used a placebo comparator rather than an active antiresorptive and did not show the same cardiovascular signal, suggesting the ARCH finding may relate in part to a protective effect of alendronate rather than an absolute risk increase with romosozumab [5]. This nuance matters when counseling patients who are apprehensive about the boxed warning.

What Virginia Patients Should Know About the 12-Month Limit

Romosozumab is approved for a maximum of 12 monthly doses. This is not an arbitrary insurance restriction. The anabolic window for sclerostin inhibition diminishes after approximately 12 months of continuous therapy, as the body upregulates sclerostin production in response to sustained antibody blockade.

Bone formation markers (P1NP) peak at around month 6 and return toward baseline by month 12, while bone resorption markers (CTX) remain suppressed throughout the treatment course. The net effect is a rapid and substantial BMD increase during the first 6 to 9 months, followed by a plateau. In the FRAME trial, lumbar spine BMD increased by 13.3% at 12 months with romosozumab versus 0.0% with placebo [5].

After completing the 12-dose course, Virginia patients must transition to a maintenance antiresorptive. Stopping romosozumab without follow-on therapy leads to rapid BMD loss, similar to the rebound phenomenon seen with denosumab discontinuation (though less severe). The AACE guideline explicitly recommends against a "drug holiday" after romosozumab; immediate sequencing to denosumab 60 mg every 6 months or zoledronic acid 5 mg IV annually is the standard of care [7].

Virginia insurers generally approve the transition PA for the follow-on agent without difficulty when the prescriber documents completion of the romosozumab course. Submit the follow-on PA at month 10 to avoid a coverage gap.